Guangdong Hybribio Biotech Co Ltd
Guangdong Hybribio Biotech Co.,Ltd. engages in the research and development, manufacture, and sale of nucleic acid molecular diagnostic products for hospitals and medical institutes. It provides in-vitro diagnostic kits for human papilloma virus, sexually transmitted diseases (STD), thalassemia, and prenatal and postnatal. The company also offers STD real time PCR kits; hepatitis B virus real-tim… Read more
Guangdong Hybribio Biotech Co Ltd (300639) - Total Assets
Latest total assets as of September 2025: CN¥4.28 Billion CNY
Based on the latest financial reports, Guangdong Hybribio Biotech Co Ltd (300639) holds total assets worth CN¥4.28 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Guangdong Hybribio Biotech Co Ltd - Total Assets Trend (2012–2024)
This chart illustrates how Guangdong Hybribio Biotech Co Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Guangdong Hybribio Biotech Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Guangdong Hybribio Biotech Co Ltd's total assets of CN¥4.28 Billion consist of 48.1% current assets and 51.9% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 15.4% |
| Accounts Receivable | CN¥1.11 Billion | 24.0% |
| Inventory | CN¥65.66 Million | 1.4% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥283.12 Million | 6.1% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2012–2024)
This chart illustrates how Guangdong Hybribio Biotech Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Guangdong Hybribio Biotech Co Ltd's current assets represent 48.1% of total assets in 2024, a decrease from 61.8% in 2012.
- Cash Position: Cash and equivalents constituted 15.4% of total assets in 2024, up from 14.0% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 6.0% of total assets, a decrease from 22.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 24.0% of total assets.
Guangdong Hybribio Biotech Co Ltd Competitors by Total Assets
Key competitors of Guangdong Hybribio Biotech Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF
|
USA | $4.51 Billion |
|
Berry Genomics Co Ltd
SHE:000710
|
China | CN¥2.34 Billion |
|
Malaysian Genomics Resource
KLSE:0155
|
Malaysia | RM20.70 Million |
|
NSN Co. Ltd
KQ:031860
|
Korea | ₩60.96 Billion |
|
JOONGANG DNM Co.Ltd
KQ:051980
|
Korea | ₩121.79 Billion |
|
GeneMatrix Inc
KQ:109820
|
Korea | ₩28.03 Billion |
|
Genoray Co. Ltd
KQ:122310
|
Korea | ₩125.67 Billion |
|
Green Cross Lab Cell Corporation
KQ:144510
|
Korea | ₩565.79 Billion |
Guangdong Hybribio Biotech Co Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Guangdong Hybribio Biotech Co Ltd generates 0.18x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Guangdong Hybribio Biotech Co Ltd is currently not profitable relative to its asset base.
Guangdong Hybribio Biotech Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.06 | 6.55 | 6.48 |
| Quick Ratio | 4.86 | 6.32 | 6.16 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.59 Billion | CN¥ 2.11 Billion | CN¥ 1.66 Billion |
Guangdong Hybribio Biotech Co Ltd - Advanced Valuation Insights
This section examines the relationship between Guangdong Hybribio Biotech Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.14 |
| Latest Market Cap to Assets Ratio | 0.07 |
| Asset Growth Rate (YoY) | -19.3% |
| Total Assets | CN¥4.62 Billion |
| Market Capitalization | $319.65 Million USD |
Valuation Analysis
Below Book Valuation: The market values Guangdong Hybribio Biotech Co Ltd's assets below their book value (0.07 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Guangdong Hybribio Biotech Co Ltd's assets decreased by 19.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Guangdong Hybribio Biotech Co Ltd (2012–2024)
The table below shows the annual total assets of Guangdong Hybribio Biotech Co Ltd from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥4.62 Billion | -19.26% |
| 2023-12-31 | CN¥5.73 Billion | -14.94% |
| 2022-12-31 | CN¥6.73 Billion | +59.08% |
| 2021-12-31 | CN¥4.23 Billion | +48.11% |
| 2020-12-31 | CN¥2.86 Billion | +120.28% |
| 2019-12-31 | CN¥1.30 Billion | +9.15% |
| 2018-12-31 | CN¥1.19 Billion | +11.09% |
| 2017-12-31 | CN¥1.07 Billion | +84.69% |
| 2016-12-31 | CN¥579.15 Million | +17.28% |
| 2015-12-31 | CN¥493.83 Million | +28.05% |
| 2014-12-31 | CN¥385.66 Million | +42.30% |
| 2013-12-31 | CN¥271.02 Million | +60.13% |
| 2012-12-31 | CN¥169.25 Million | -- |